nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.03.2012 | Letter to the Editor

Suggested pathway to assess radiation safety of ¹¹C-labeled PET tracers for first-in-human studies

verfasst von: Paolo Zanotti-Fregonara, Robert B. Innis

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Excerpt

Dear Sir, …

Sparks RB, Aydogan B. Comparison of the effectiveness of some common animal data scaling techniques in estimating human radiation dose. Sixth International Radiopharmaceutical Dosimetry Symposium. Stelson AS, editor. Oak Ridge:Associated Universities; 1999. p. 705–716.

Sprague DR, Fujita M, Ryu YH, Liow JS, Pike VW, Innis RB. Whole-body biodistribution and radiation dosimetry in monkeys and humans of the phosphodiesterase 4 radioligand [(11)C](R)-rolipram: comparison of two-dimensional planar, bisected and quadrisected image analyses. Nucl Med Biol 2008;35:493–500.PubMedCrossRef

Brown AK, Fujita M, Fujimura Y, Liow J-S, Stabin M, Ryu YH, et al. Radiation dosimetry and biodistribution in monkey and man of 11C-PBR28, a PET radioligand to image inflammation. J Nucl Med 2007;48:2072–9.PubMedCrossRef

NIH RSC report: improving informed consent for research radiation studies, 10/17/2001.

Gatley SJ. Estimation of upper limits on human radiation absorbed doses from carbon-11-labeled compounds. J Nucl Med 1993;34:2208–15.PubMed

Parsey RV, Belanger MJ, Sullivan GM, Simpson NR, Stabin MG, Van Heertum R, et al. Biodistribution and radiation dosimetry of 11C-WAY100,635 in humans. J Nucl Med 2005;46:614–9.PubMed

Parsey RV, Sokol LO, Bélanger MJ, Kumar JS, Simpson NR, Wang T, et al. Amyloid plaque imaging agent [C-11]-6-OH-BTA-1: biodistribution and radiation dosimetry in baboon. Nucl Med Commun 2005;26:875–80.PubMedCrossRef

Thees S, Neumaier B, Glatting G, Deisenhofer S, von Arnim CA, Reske SN, et al. Radiation dosimetry and biodistribution of the beta-amyloid plaque imaging tracer 11C-BTA-1 in humans. Nuklearmedizin 2007;46:175–80.PubMed

Tipre DN, Fujita M, Chin FT, Seneca N, Vines D, Liow JS, et al. Whole-body biodistribution and radiation dosimetry estimates for the PET dopamine transporter probe 18F-FECNT in non-human primates. Nucl Med Commun 2004;25:737–42.PubMedCrossRef

10.

Lu JQ, Ichise M, Liow JS, Ghose S, Vines D, Innis RB. Biodistribution and radiation dosimetry of the serotonin transporter ligand 11C-DASB determined from human whole-body PET. J Nucl Med 2004;45:1555–9.PubMed

11.

Hines CS, Liow JS, Zanotti-Fregonara P, Hirvonen J, Morse C, Pike VW, et al. Human biodistribution and dosimetry of 11C-CUMI-101, an agonist radioligand for serotonin-1a receptors in brain. PLoS One 2011;6:e25309.PubMedCrossRef

12.

NIMH/SNIDD tracer database initiative. http://pdsp.med.unc.edu/snidd/ Accessed 17 Mar 2011.

13.

Terry GE, Hirvonen J, Liow JS, Seneca N, Tauscher JT, Schaus JM, et al. Biodistribution and dosimetry in humans of two inverse agonists to image cannabinoid CB1 receptors using positron emission tomography. Eur J Nucl Med Mol Imaging 2010;37:1499–506.PubMedCrossRef

14.

Liow JS, Kreisl W, Zoghbi SS, Lazarova N, Seneca N, Gladding RL, et al. P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys. J Nucl Med 2009;50:108–15.PubMedCrossRef

15.

Seneca N, Zoghbi SS, Liow JS, Kreisl W, Herscovitch P, Jenko K, et al. Human brain imaging and radiation dosimetry of 11C-N-desmethyl-loperamide, a PET radiotracer to measure the function of P-glycoprotein. J Nucl Med 2009;50:807–13.PubMedCrossRef

16.

Hirvonen J, Roivainen A, Virta J, Helin S, Någren K, Rinne JO. Human biodistribution and radiation dosimetry of 11C-(R)-PK11195, the prototypic PET ligand to image inflammation. Eur J Nucl Med Mol Imaging 2010;37:606–12.PubMedCrossRef

17.

Kumar A, Muzik O, Chugani D, Chakraborty P, Chugani HT. PET-derived biodistribution and dosimetry of the benzodiazepine receptor-binding radioligand (11)C-(R)-PK11195 in children and adults. J Nucl Med 2010;51:139–44.PubMedCrossRef

18.

Herscovitch P, Schmall B, Doudet D, Carson R, Eckelman WC. Biodistribution and radiation dose estimates for [C-11]raclopride. J Nucl Med 1997;38:224P.

19.

Slifstein M, Hwang DR, Martinez D, Ekelund J, Huang Y, Hackett E, et al. Biodistribution and radiation dosimetry of the dopamine D2 ligand 11C-raclopride determined from human whole-body PET. J Nucl Med 2006;47:313–9.PubMed

20.

Ribeiro MJ, Ricard M, Bourgeois S, Lièvre MA, Bottlaender M, Gervais P, et al. Biodistribution and radiation dosimetry of [11C]raclopride in healthy volunteers. Eur J Nucl Med Mol Imaging 2005;32:952–8.PubMedCrossRef

21.

Graham MM, Peterson LM, Muzi M, Graham BB, Spence AM, Link JM, et al. 1-[Carbon-11]-glucose radiation dosimetry and distribution in human imaging studies. J Nucl Med 1998;39:1805–10.PubMed

22.

Laymon CM, Mason NS, Frankle WG, Carney JP, Lopresti BJ, Litschge MY, et al. Human biodistribution and dosimetry of the D2/3 agonist 11C-N-propylnorapomorphine (11C-NPA) determined from PET. J Nucl Med 2009;50:814–7.PubMedCrossRef

23.

Treyer V, Streffer J, Ametamey SM, Bettio A, Bläuenstein P, Schmidt M, et al. Radiation dosimetry and biodistribution of 11C-ABP688 measured in healthy volunteers. Eur J Nucl Med Mol Imaging 2008;35:766–70.PubMedCrossRef

24.

Thierens H, van Eijkeren M, Goethals P. Biokinetics and dosimetry for [methyl-11C]thymidine. Br J Radiol 1994;67:292–5.PubMedCrossRef

25.

Bullich S, Slifstein M, Passchier J, Murthy NV, Kegeles LS, Kim JH, et al. Biodistribution and radiation dosimetry of the glycine transporter-1 ligand (11)C-GSK931145 determined from primate and human whole-body PET. Mol Imaging Biol 2011;13:776–84.PubMedCrossRef

26.

Tolvanen T, Någren K, Yu M, Sutinen E, Havu-Aurén K, Jyrkkiö S, et al. Human radiation dosimetry of [11C]MeAIB, a new tracer for imaging of system A amino acid transport. Eur J Nucl Med Mol Imaging 2006;33:1178–84.PubMedCrossRef

27.

Liu N, Li M, Li X, Meng X, Yang G, Zhao S, et al. PET-based biodistribution and radiation dosimetry of epidermal growth factor receptor-selective tracer 11C-PD153035 in humans. J Nucl Med 2009;50:303–8.PubMedCrossRef

28.

Virta JR, Tolvanen T, Någren K, Bruck A, Roivainen A, Rinne JO. 1-11C-methyl-4-piperidinyl-N-butyrate radiation dosimetry in humans by dynamic organ-specific evaluation. J Nucl Med 2008;49:347–53.PubMedCrossRef

29.

Tolvanen T, Yli-Kerttula T, Ujula T, Autio A, Lehikoinen P, Minn H, et al. Biodistribution and radiation dosimetry of [(11)C]choline: a comparison between rat and human data. Eur J Nucl Med Mol Imaging 2010;37:874–83.PubMedCrossRef

30.

Newberg AB, Ray R, Scheuermann J, Wintering N, Saffer J, Schmitz A, et al. Dosimetry of 11C-carfentanil, a micro-opioid receptor imaging agent. Nucl Med Commun 2009;30:314–8.PubMedCrossRef

31.

van der Veldt AA, Hendrikse NH, Smit EF, Mooijer MP, Rijnders AY, Gerritsen WR, et al. Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients. Eur J Nucl Med Mol Imaging 2010;37:1950–8.PubMedCrossRef

32.

Scheinin NM, Tolvanen TK, Wilson IA, Arponen EM, Någren KA, Rinne JO. Biodistribution and radiation dosimetry of the amyloid imaging agent 11C-PIB in humans. J Nucl Med 2007;48:128–33.PubMed

33.

Santens P, De Vos F, Thierens H, Decoo D, Slegers G, Dierckx RA, et al. Biodistribution and dosimetry of carbon-11-methoxyprogabidic acid, a possible ligand for GABA-receptors in the brain. J Nucl Med 1998;39:307–10.PubMed

34.

Seltzer MA, Jahan SA, Sparks R, Stout DB, Satyamurthy N, Dahlborn M, et al. Radiation dose estimates in humans for (11)C-acetate whole-body PET. J Nucl Med 2004;45:1233–6.PubMed

35.

Nugent AC, Neumeister A, Drevets WC, Eckelman WC, Channing MA, Herscovitch P. Human biodistribution and dosimetry of the PET benzodiazepine receptor ligand [11C]flumazenil. J Nucl Med 2004;45(Suppl):434P.

36.

Deloar HM, Fujiwara T, Nakamura T, Itoh M, Imai D, Miyake M, et al. Estimation of internal absorbed dose of L-[methyl-11C]methionine using whole-body positron emission tomography. Eur J Nucl Med 1998;25:629–33.PubMedCrossRef

37.

O’Keefe GJ, Saunder TH, Ng S, Ackerman U, Tochon-Danguy HJ, Chan JG, et al. Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172. J Nucl Med 2009;50:309–15.PubMedCrossRef

38.

Cropley VL, Fujita M, Musachio JL, Hong J, Ghose S, Sangare J, et al. Whole-body biodistribution and estimation of radiation-absorbed doses of the dopamine D1 receptor radioligand, (11)C-NNC 112, in humans. J Nucl Med 2006;47:100–4.PubMed

39.

Ribeiro MJ, Ricard M, Lièvre MA, Bourgeois S, Emond P, Gervais P, et al. Whole-body distribution and radiation dosimetry of the dopamine transporter radioligand [(11)C]PE2I in healthy volunteers. Nucl Med Biol 2007;34:465–70.PubMedCrossRef

40.

Marthi K, Hansen SB, Jakobsen S, Bender D, Smith SB, Smith DF. Biodistribution and radiation dosimetry of [N-methyl-11C]mirtazapine, an antidepressant affecting adrenoceptors. Appl Radiat Isot 2003;59:175–9.PubMedCrossRef

Titel: Suggested pathway to assess radiation safety of 11C-labeled PET tracers for first-in-human studies
verfasst von: Paolo Zanotti-Fregonara
Robert B. Innis
Publikationsdatum: 01.03.2012
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 3/2012
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-011-2005-8

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Suggested pathway to assess radiation safety of ¹¹C-labeled PET tracers for first-in-human studies

Excerpt

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Can FDG PET/CT monitor the response to hormonal therapy in breast cancer patients?

18F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation

Monitoring anti-inflammatory therapies in patients with atherosclerosis: FDG PET emerges as the method of choice

18F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: implications for future clinical trials

Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine: a clarification

18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma